This study was conducted in order to investigate the implications of the @entity7820 polymorphism in the @entity876 gene in @entity0 risk. The enlightenment of this matter might provide a piece of information about the potential implications of this polymorphism in @entity1 risk. A meta-analysis was conducted considering a large sample size from studies with conflicting results on the @entity7820 polymorphism in @entity0 @entity1 . Relevant studies were selected from PubMed and SciELO databases for data extraction and statistical analysis. Database was built according to the continent and considering the genotype frequencies, sample size and genotyping methodology. The dominant models (RR vs @entity6391 + PP and RR + @entity6391 vs. PP), homozygous (RR vs. PP), heterozygous (RR vs. @entity6391 and @entity6391 vs. PP) and the allele (R vs. P) were used. Genotype frequencies were summarized and evaluated by   (2) test of heterogeneity in 2*2 contingency tables with 95% CIs. Odds Ratios (OR) were calculated with a fixed-effect model (Mantel-Haenszel) or a random-effect model (DerSimonian-Laird) if the studies were considered homogeneous (P > 0.05) or heterogeneous (P < 0.05), respectively, using BioEstat   5.0 software. Supported by a large sample size composed by 25,629 cases and 26,633 controls from 41 studies, we found significant association between the @entity7820 polymorphism in the @entity876 gene and the @entity0 risk. The overall data shows an increased risk due to the P allele dominant model, but not in Asia where the risk was associated with the R allele and R dominant model.

Association of the @entity876 codon 72 polymorphism and XXXX risk: a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity6391 :: ('MESH:D012174', 'Disease') :: ['RP'] @entity876 :: ('7157', 'Gene') :: ['TP53'] @entity7820 :: ('p|SUB|R|72|P', 'ProteinMutation') :: ['R72P']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
